Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

This trial is testing a combination of three drugs — ivosidenib, venetoclax, and sometimes azacitidine — in patients with blood cancers (like AML or MDS) that carry a specific genetic mutation called IDH1, to see if the combination can achieve or improve remission. **You may be eligible if...** - You are over 18 years old - Your cancer has the IDH1-R132 genetic mutation (found through lab testing) - You have relapsed or treatment-resistant AML (acute myeloid leukemia), OR you have newly diagnosed AML but cannot tolerate standard intensive chemotherapy, OR you have high-risk MDS or related bone marrow disorders that have not responded to other therapy - Your liver and kidney function are within acceptable ranges **You may NOT be eligible if...** - You are allergic to ivosidenib or venetoclax - You have previously received either of these two drugs - You have active, uncontrolled infections or serious psychiatric illness - You have active graft-versus-host disease (GVHD) following a prior stem cell transplant - You are currently taking strong CYP3A enzyme-interacting medications (certain antibiotics, antifungals, anticonvulsants) Talk to your doctor to see if this trial is right for you.